RNF180

RNF180 Full Name

ring finger protein 180

RNF180 Introduction

RNF180 (ring finger protein 180) is a RING-domain E3 ubiquitin ligase that has emerged as a tumor suppressor with a particularly strong connection to gastric cancer, the cancer type in which its silencing was first and most thoroughly documented. The RNF180 gene is frequently inactivated in gastric tumors through methylation of its promoter, and loss of RNF180 expression correlates with aggressive tumor behavior and poor patient survival, indicating that the protein normally restrains the growth and spread of gastric epithelial cells. Functional studies support this view: restoring RNF180 in cancer cell lines suppresses proliferation, induces apoptosis, and reduces migration and invasion, effects that are consistent with the ubiquitylation and degradation of pro-tumorigenic substrates. Because methylation of the RNF180 promoter can be detected not only in tumor tissue but also in the circulating DNA of patients, RNF180 methylation has been evaluated as a non-invasive biomarker for the early detection and monitoring of gastric cancer. The broader relevance of RNF180 is suggested by reports of its downregulation in hepatocellular and other carcinomas, where it may similarly act to restrain malignant progression. Ongoing efforts are focused on identifying the substrates through which RNF180 exerts its tumor-suppressive effects and on exploiting its epigenetic silencing for clinical diagnosis.

Figure 1. The structure of RNF180.

RING Finger E3 Ligase Features and Epigenetic Regulation
The RNF180 protein contains a RING finger domain that confers E3 ubiquitin ligase activity, allowing it to promote the ubiquitin-dependent degradation or functional modification of its substrates.
Regions flanking the RING domain support substrate recognition and interactions with the ubiquitin-conjugating enzymes that deliver activated ubiquitin.
The RNF180 gene is located on human chromosome 5, and its promoter lies within a CpG island whose methylation status governs transcriptional activity.
In normal tissues RNF180 is expressed at moderate levels in epithelial cells, whereas in a large proportion of gastric cancers the promoter becomes hypermethylated and the gene is silenced.
This epigenetic silencing is an early event in gastric carcinogenesis in many cases, and the methylation can be reversed experimentally with demethylating agents, which restores RNF180 expression and tumor-suppressive activity.
The abundance of RNF180 is also controlled post-translationally, with the ligase itself subject to ubiquitin-dependent turnover.
Because promoter methylation provides a stable, quantifiable mark of gene inactivation, RNF180 exemplifies how epigenetic lesions can serve both as drivers of cancer and as molecular readouts of disease.

Tumor Suppression in Gastric Cancer and Biomarker Applications
Gastric cancer cells that have lost RNF180 expression show enhanced proliferation and survival, whereas enforced expression of the ligase slows growth, promotes apoptosis, and impairs the motility and invasive capacity of tumor cells.
Mechanistic studies suggest that RNF180 ubiquitylates and destabilizes proteins that promote oncogenic signaling, thereby dampening the pathways that drive gastric tumor progression.
Clinicopathological analyses consistently associate reduced RNF180 protein or promoter hypermethylation with advanced tumor stage, lymph node metastasis, and shorter survival in gastric cancer patients.
Because tumor-derived DNA carrying methylated RNF180 promoter sequences can be detected in the blood, assays for RNF180 methylation are being developed as liquid-biopsy tools for the early detection, risk stratification, and monitoring of gastric cancer.
RNF180 downregulation has also been reported in hepatocellular carcinoma and other tumor types, suggesting that its tumor-suppressive function is not restricted to the stomach.
These findings identify RNF180 both as a mechanistic contributor to gastrointestinal malignancy and as a clinically actionable biomarker, and they motivate the search for the ligase's physiological substrates as potential therapeutic targets.

Alternate Names for RNF180

RNF180; ring finger protein 180; E3 ubiquitin-protein ligase RNF180; MGC120326; MGC120328;